Browsing Tag
Amgen
48 posts
Lundbeck’s Vyepti shows real-world migraine relief in patients failed by prior CGRP treatments
New INFUSE study data shows Vyepti may improve outcomes in migraine patients unresponsive to CGRP therapies. Find out what this means for the market.
Amgen (NASDAQ: AMGN) expands TrumpRx pricing deal, offers Aimovig and Amjevita at $299
Amgen cuts U.S. drug prices for Aimovig and Amjevita under TrumpRx, citing earlier investments in Ohio and North Carolina. See what this signals for big pharma.
Can UPLIZNA transform gMG treatment? Amgen’s FDA win sets new benchmark for antibody-positive patients
Discover how Amgen’s UPLIZNA is redefining generalized myasthenia gravis treatment after FDA approval. Find out what this means for patients and investors.
Why Pfizer’s $10bn Metsera deal could reshape the obesity drug market in 2026 and beyond
Pfizer beats Novo Nordisk in $10B Metsera buyout, reshaping obesity drug competition. Find out what this means for the pharma M&A and GLP-1 space.
Tezspire gains FDA approval for CRSwNP, expanding AstraZeneca and Amgen’s reach in inflammatory airway diseases
Tezspire gets FDA approval for chronic rhinosinusitis with nasal polyps. See how AstraZeneca and Amgen are expanding the respiratory biologics frontier.
Amgen and AstraZeneca win FDA approval for Tezspire in chronic rhinosinusitis with nasal polyps
Find out how Amgen and AstraZeneca’s Tezspire approval for nasal polyps redefines biologic therapy and reshapes investor confidence today.
Biocon wins U.S. launch date for Prolia and Xgeva biosimilars—Can Amgen keep investors calm?
Amgen settles with Biocon for denosumab biosimilars, paving way for Bosaya and Aukelso U.S. launch from Oct 2025. What this means for biotech and investors.
Nyrada Inc (ASX: NYR) stock draws fresh attention as investors eye trial milestones in 2025
Nyrada Inc (ASX: NYR) stock is moving on higher volumes as trial milestones near. Find out why investors are watching this biotech in 2025.
Amgen and Kyowa Kirin report Phase 3 rocatinlimab results highlighting long-term safety and durable response in atopic dermatitis
Amgen and Kyowa Kirin report Phase 3 rocatinlimab results showing long-term safety and durable efficacy in atopic dermatitis. Find out what comes next.
FDA acceptance of Sarfaraz Niazi’s biosimilar petition could reset the economics of monoclonal antibody approvals
FDA accepts Sarfaraz Niazi’s petition to waive costly clinical efficacy studies for monoclonal antibody biosimilars, reshaping drug affordability worldwide.